(Q38177771)

30 August 2017

title

TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia (English)

1 reference

30 August 2017

0 references

Jitka Malcikova

1

1 reference

30 August 2017

Sarka Pavlova

series ordinal

2

1 reference

30 August 2017

Katerina Stano Kozubik

series ordinal

3

1 reference

30 August 2017

Sarka Pospisilova

series ordinal

4

1 reference

30 August 2017

language of work or name

1 reference

5 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

35

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

663-671

1 reference

Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

What is the best frontline therapy for patients with CLL and 17p deletion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

p53-mediated hematopoietic stem and progenitor cell competition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The emerging role of p53 in stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

p53 in chronic myelogenous leukemia in acute phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Ultrasensitive detection of rare mutations using next-generation targeted resequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A simple p53 functional assay for screening cell lines, blood, and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line: a novel mechanism of p53 gene inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Immunological aspects in chronic lymphocytic leukemia (CLL) development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The genomic landscape of hypodiploid acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

p53 regulates hematopoietic stem cell quiescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Performance comparison of benchtop high-throughput sequencing platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Next-generation DNA sequencing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Identification and correction of systematic error in high-throughput sequence data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Sequencing technologies - the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Clinical outcomes and correlates of TP53 mutations and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Cellular origin and pathophysiology of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

What do we do with chronic lymphocytic leukemia with 17p deletion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Next-generation sequencing transforms today's biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Assessing TP53 status in human tumours to evaluate clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Germline TP53 mutations and Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

p53 lesions in leukemic transformation

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.22508

7 January 2021

Identifiers

DOI

10.1002/HUMU.22508

1 reference

30 August 2017

1 reference